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AbstrACt
Objective To understand the importance of electronic 
nicotine delivery systems (ENDS) product attributes to 
adult consumers in the USA by age and gender.
Design Cross-sectional survey with a discrete choice 
experiment (best–worst, case 2, scaling) of 19 choice 
tasks in which participants answered what would make 
them most want to use and least want to use an ENDS 
product.
setting and participants A national sample of adults 
(aged 18+ years) in the USA who had tried an ENDS 
product at least once.
Measures We included 9 ENDS attributes with levels that 
varied across 19 choice tasks. We performed a multinomial 
logistic regression to obtain overall importance scores, 
attribute-level part-worth utilities and most important 
attribute.
results Of 660 participants, 81% were white, 51% 
women and 37% had at least a 4-year college degree with 
an average age of 42.0 years (SD ±19.4). The attributes 
had the following importance: harms of use 17.6%; 
general effects 14.1%; cessation aid 12.6%; purchase 
price 12.1%; monthly cost 12.0%; nicotine content 11.4%; 
flavour availability 8.4%; device design 7.2%; modifiability 
4.6%. Harms of use was the most important attribute for 
all ages and genders (p<0.05); variation in other important 
attributes existed by age though not by gender.
Conclusion This study identified the importance of nine 
ENDS attributes. Perceived harms of use of ENDS use 
appeared most important, and modifiability was least 
important. Variation by consumer group existed, which 
may allow for targeted interventions to modify ENDS use.
IntrODuCtIOn
Although its health effects remain unclear, 
the use of electronic nicotine delivery systems 
(ENDS) in the USA continues to grow even 
in the face of impending regulation.1 While 
the use of combustible tobacco cigarettes 
has declined, the US ENDS market now 
exceeds $8 billion.2 3 The rise in the use of 
ENDS has occurred despite mixed evidence 
about its harm reduction effects or use as a 
tobacco cessation aid.4 Given the uncertainty 
around ENDS, initial regulations were piece-
meal and varied from state to state. However, 
in 2016, the Food and Drug Administration 
(FDA) issued a regulation deeming ENDS 
to fall under its authority.5 These regula-
tions will impose a variety of restrictions on 
ENDS manufacturing, sales and marketing. 
Notably, however, the FDA has postponed 
implementation of some of the rules require-
ments, citing the possibility that ENDS have 
the ‘potential to make a notable public health 
difference’.6 As the potential benefits and 
harms of ENDS become clear, regulators and 
public health groups will need to understand 
how their proposed regulations will likely 
affect consumers’ use. Consumers use ENDS 
due to a variety of product attributes that may 
be amenable to regulation or public health 
campaigns.7 Regulators and public health 
groups need to know the incremental role of 
individual product attributes on the decision 
to use ENDS products so that they can make 
strengths and limitations of this study:
 ► Large US sample using a robust experimental de-
sign, a best–worst scaling, case 2 method, incor-
porating large numbers of relevant attributes of
electronic nicotine delivery systems (ENDS).
 ► Consumers found different attributes of ENDS prod-
ucts important to their use.
 ► Perceived harms of ENDS use appeared most im-
portant to their choice of ENDS products, and modi-
fiability was least important.
 ► Variation by consumer group existed, which may
allow for targeted interventions to modify ENDS use.
 ► Limitations include the convenience sample of US
ENDS users, and the use of an experimental design
which may invite more socially acceptable respons-
es as opposed to direct purchasing observations.
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evidence-based policies depending on how they want to 
modify ENDS use.
A widely used method in behavioural economics to 
understand consumer use is discrete choice experiments 
(DCE).8 9 Once the relationship between consumers’ 
use and product attributes is understood, regulators can 
consider whether and how to address the most important 
attributes to most of the consumers to either increase or 
decrease product use. While DCEs have been conducted 
to examine consumers’ attitudes towards combustible 
tobacco regulations and smoking cessation,10–14 only 
one has examined potential ENDS use.15 This recently 
published study conducted in Canada examined only four 
ENDS attributes: flavour, nicotine content, health warn-
ings and price15; finding that health risks and efficacy as 
a tobacco cessation aid were the two most important attri-
butes to consumers. However, this study only examined 
four attributes and included non-smokers and non-ENDS 
users.
Knowledge from our formative qualitative work was 
used to create a DCE with a larger number of attributes 
focused on ENDS users. We examined the list of a dozen 
attributes that are important to consumers, which we 
developed from a recent structured content analysis.16 
Among these 12 attributes, we found 9 attributes that 
appeared related to the ENDS device itself.16 We chose 
to look at the device-related attributes because these attri-
butes may be more easily regulated than other psycho-
social attributes such as the ability to vape in public or 
as a social outlet.17 18 We designed and fielded a DCE 
study using a best–worst scaling experiment among the 
national US sample of ENDS users.
MethODs
study design
We conducted a one-time survey including a best–worst 
scaling, case 2 design DCE of the importance of ENDS 
product attributes. The final version of the survey was 
fielded using the Research Now survey panel between 
26 August and 31 August 2016. Participants were remu-
nerated from Research Now in accordance with their 
usual rate.
Patient and public involvement
The attributes used in the DCE were developed through 
focus groups conducted as part of prior research.19 The 
study involved participants in a pretest phase using an 
academic mass email system. Twelve individuals pretested 
the survey between 9 May and 14 May 2016. Incentive 
for completing the survey included possibly receiving 
one of four gift cards valued at $50 each. Feedback from 
the pretest led to both condensing and simplifying the 
language of the survey. Clarity of the survey was again 
improved after another round of testing with 75 survey 
panellists recruited from Research Now, a research survey 
company, between 15 August and 16 August 2016. The 
second episode of testing also led to language alterations 
surrounding questions on the flavour attribute and its 
levels to ensure comprehension. Participants were not 
involved in the recruitment to or conduct of the study. 
Participants in the final version of the survey did not 
receive their study results.
Participants
We recruited 660 members of the Research Now survey 
panel aged 18 years and older who reported having used 
ENDS at least once in their lifetime to complete the 
ENDS survey. Research Now is one of the major online 
survey panel companies with over 140 million finished 
surveys annually. Participants had to live in the USA and 
be able to complete an electronic survey in English. We 
specifically oversampled for older adults and minimum 
quotas to ensure near equal balance of gender.
survey design
The survey was designed to include a best–worst scaling 
experiment related to ENDS use followed by a series of 
tobacco and ENDS-related questions. The survey included 
19 best–worst scaling choice tasks, followed by questions 
on each participant’s demographics, personality, current 
and past use of ENDS and tobacco products and prior 
attempts to quit tobacco use. Sawtooth Software was used 
to design the survey. Prior to the best–worst tasks, the 
survey provided an explanation for each of the attributes, 
as well as an example task involving car attribute prefer-
ence followed by an example of a best–worst scaling task 
(figure 1). The participants were told that some of the 
attributes were real but others were not and were asked, 
for the purposes of the study, to pretend they were all real 
and imagine each choice task as a new device. As opposed 
to other types of DCE methods where consumers choose 
between ENDS products, for each of the 19 choice tasks, 
participants selected one of five listed attribute levels 
that they felt most likely to encourage and least likely 
to encourage their use of a theoretical ENDS product. 
While other approaches such as a classical DCE would 
also yield importance scores, past studies demonstrated 
user fatigue and attribute dominance due to complex 
Figure 1 Example of a best–worst scaling, case 2 task.
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and overwhelming survey questions, whereas best–worst 
scaling, though not case 2, has been used in other areas 
of tobacco control.20–23 Additionally, best–worst scaling 
case 2 methodology was preferred because it leads to 
scores on a common scale, permitting direct comparison 
between all attribute levels within the study, but not just 
direct comparisons among levels within the same attri-
bute (as is the case for other DCE methods).24 25 The 660 
participants received 1 of 50 versions of the survey using 
a partial profile design. We sought efficiency by using 
a computer search algorithm to generate a design that 
showed each of a given attribute's levels an equal number 
of times (one-way level balance) and each pairing of a 
given attribute level with the levels of other attributes an 
equal number of times (two-way level balance that reduces 
correlations among the attributes). These two criteria will 
maximise both level balance and orthogonality, the two 
constituents of design efficiency for experimental design 
for a set of single profiles. Overall, each attribute level was 
seen about three times per participant (2.97), and each 
valid cross-attribute pair was seen not quite half the time 
by each participant (0.42 times). Reliable best–worst utili-
ties can be obtained as long as each participant sees each 
level about three times.26 The order of attributes varied 
across the survey blocks so that positional balance was 
maintained.
best–worst scaling attributes and levels
The nine attributes were included with a definition in the 
survey. Their definitions can be found in online appendix 
table 1. For the rest of the paper, we will refer to these nine 
as harms of use, general effects, cessation aid, purchase price, 
monthly cost, nicotine content, flavour availability, device design 
and modifiiability.16 We chose to divide cost into a sepa-
rate purchase price and monthly cost attributes because 
of the variation that can be seen in each; the focus group 
members mentioned the two attributes separately as 
well. Rates of tobacco cessation for ENDS products were 
drawn from the evidence that ENDS are often used as a 
tobacco cessation aid regardless of actual effectiveness. It 
is worth noting that medications prescribed for assisting 
in tobacco cessation (eg, bupropion, varenicline, nico-
tine containing products) have 2 out of 10 success rate 
at best.27 Nicotine content levels were drawn from the 
current spectrum of labelled nicotine concentrations.28 
In addition to the actual concentration, we included a 
label of ‘none’, ‘low’, etc., to denote where a particular 
concentration falls in the range of concentrations.
Other measures
Participants responded to questions about sex, age, race 
and ethnicity, perceptions of general health,29 educa-
tion level and yearly household income. The survey then 
collected details about each participants’ tobacco and 
ENDS use behaviours. Items included the heaviness of 
smoking index that asks participants ‘At present, how long 
after waking do you wait before having your first cigarette 
(in mins)?’ and ‘How many cigarettes do you smoke per 
day at present?’30 and other questions from the National 
Adult Tobacco Survey Questionnaire, 2012–2013, such as 
age of first cigarette, number of cigarettes smokes per day 
and smoking days per month.31
Analysis
In DCEs, respondents are given tasks that combine 
possible varieties of product attributes and asked to make 
a choice, in our case, which attribute of the product was 
important to their use. With enough choice tasks, esti-
mated importance scores can be generated, indicating 
which attribute most influenced their choices. The statis-
tical model underlying best–worst scaling assumes that 
the relative choice probability of a given pair of best–
worst choices is proportional to the distance between 
the two attribute levels on the latent utility scale. The 
pair of attribute levels chosen maximises the difference 
in the part-worth utilities for a given choice task. These 
distances between attribute levels are modelled as a 
difference model, with variations on best–worst scaling 
sometimes called ‘maximum difference scaling’.32 Using 
a multinomial regression model, these differences can 
provide the part-worth utilities relative to a single attri-
bute level rather than relative to the sample mean.24 
Part-worth utilities are zero-centred numerical values that 
represent the relative desirability of the levels within each 
attribute. The higher the number, the more desirable 
the attribute’s level is to participants. Importance scores 
were then calculated based on the difference between 
minimum and maximum part-worth utilities within an 
attribute.25 33 The total importance of all attributes to a 
decision is 100%, with each attribute given a percentage 
of that total importance. Most important attribute was 
determined by comparing the importance scores for 
each individual, defining the attribute with the largest 
importance score as most important. In order to examine 
changes in attribute importance by age and gender, we 
performed a dependent z-test of proportions to compare 
the most important attribute with the next highest ranked 
attribute by age and gender.
results
Of 900 individuals surveyed, 660 participants had used 
ENDS at least one time. Participants had a mean age 
of 42 years (SD ±19.4) with a range from 18 to 82 years 
and were evenly split women versus men (51% vs 49%) 
(table 1). Most participants were white (81%), making 
less than $60 000 annually (60%) and self-reported very 
good or excellent health (60%). Sixty-four percent had 
used ENDS in the last 30 days. Almost all participants 
(92%) reported a history of traditional tobacco products 
and most (85%) had tried to quit tobacco in the past 12 
months. Pearson’s χ2 tests of the relation between age 
and tobacco use characteristics found statistically signif-
icant (p<0.05) differences between subgroups of young 
(18–24 years), middle-aged (25–49 years) and older 
(50+ years) adults. For example, young adult participants 
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were more likely to have used ENDS in the last 30 days 
(p=0.036) and to have used flavoured ENDS (p=0.012). 
Older adults were less likely to have used ENDS in the 
past 30 days (p<0.001) and more likely to smoke one 
pack/day of traditional tobacco (p<0.001) (see table 2).
Importance of enDs attributes overall and by subgroup
The overall importance scores for the nine attributes 
are found in figure 2. The attributes had the following 
importance distribution: harms of use 17.6%; general 
effects 14.1%; cessation aid 12.6%; purchase price 12.1%; 
monthly cost 12.0%; nicotine content 11.4%; flavour avail-
ability 8.4%; device design 7.2% and modifiability 4.6%. 
Independent t-tests of the importance scores by gender 
found that when compared with men, women partic-
ipants were more likely to give importance to harms 
of uses (∆+9.7%; p<0.001) and general effects (∆+8.1%; 
p=0.002) and less likely to give importance to purchase 
price (∆−8.3%; p=0.011) and monthly cost (∆−6.8%; 
p=0.008).
Numerous statistically significant differences were 
found by age subgroups. Younger adults compared 
with middle-aged and older adults together were 
more likely to give importance to modifiability (∆+22%; 
p=0.004) and less likely to give importance to purchase 
price (∆−11%; p=0.006). Middle-aged adults compared 
with young and older adults together were more likely 
to give importance to modifiability (∆+24%; p=0.001) 
and less likely to give importance to harms of use (∆−5%; 
p=0.027). Older adults compared with middle-aged and 
young adults together were more likely to give impor-
tance to purchase price (∆+11%; p=0.004) and less likely 
to give importance to modifiability (∆−34%; p<0.001).








Age, mean (SD) 42.0 (19.4) 22.2 (1.6) 32.1 (7.7) 65.0 (6.9)
Female 334 (51%) 90 (53%) 120 (49%) 124 (50%)
Race
 White 532 (81%) 113 (67%) 191 (79%) 228 (92%)
 Black 42 (6%) 14 (8%) 18 (7%) 10 (4%)
 Asian-American 40 (6%) 20 (12%) 18 (7%) 2 (1%)
 Other 46 (7%) 22 (13%) 15 (6%) 9 (4%)
Hispanic or Latino/Latina 94 (14%) 42 (25%) 45 (19%) 7 (3%)
College degree or higher 247 (37%) 37 (22%) 113 (47%) 97 (38%)
Overall health, very good or excellent 396 (60%) 110 (65%) 160 (66%) 126 (51%)
Annual household income
 $0 to $29 999 149 (23%) 52 (31%) 51 (21%) 46 (18%)
 $30 000 to $59 999 247 (37%) 75 (44%) 85 (35%) 87 (35%)
 $60 000 to $89 999 156 (24%) 25 (15%) 73 (30%) 58 (23%)
 $90 000 or more 106 (16%) 17 (10%) 33 (14%) 58 (23%)
Knowledge that quitting smoking with help is 
more successful than without
310 (47%) 75 (44%) 108 (45%) 127 (51%)
 Used ENDS in last 30 days† 387 (64%) 109 (71%) 153 (69%)* 125 (54%)*
Used flavoured ENDS in last 30 days, of current 
ENDS users‡ 
296 (70%) 93 (79%)* 134 (79%)* 69 (52%)*
 Anticipates ENDS use in next year 478 (72%) 121 (72%) 193 (80%)* 164 (66%)*
 Ever used traditional tobacco products 607 (92%) 154 (91%) 221 (91%) 232 (93%)
 Age at first cigarette, mean (SD)† 17 (6) 16 (3) 18 (5) 18 (8)
 Smokes more than one pack/day§ 54 (12%) 3 (3%)* 12 (8%)* 39 (23%)*
First smoke within 30 min of waking‡§ 256 (59%) 48 (44%)* 89 (59%) 119 (70%)*
Tobacco quit attempt in past 12 months§ 369 (85%) 87 (79%)* 130 (85%) 152 (89%)
*P<0.05; test versus total.
†n=607, 154, 221 and 232, respectively. 
‡n=420, 117, 170 and 133, respectively. 
§n=432, 110, 152 and 170, respectively.
ENDS, electronic nicotine delivery systems.
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Part-worth utilities of enDs attribute levels
The part-worth utility scores for the levels of the nine 
attributes are shown in table 2. Harms of use had the level 
with the highest part-worth utility of 88.96 (90% CI: 84.79, 
93.13), followed by general effects with a level at 58.37 (90% 
CI: 55.07, 61.68) and purchase price at 52.41 (90% CI: 
49.12, 55.70). Cessation aid had the level with the lowest 
part-worth utility of −49.11 (90% CI: −52.46,–45.75), 
followed by harms of use at −47.27 (90% CI: −49.69,–44.86).
Most important enDs attribute overall and by subgroup
After examining the importance scores for each indi-
vidual, harms of uses was the most important attribute for 
49% of participants (table 3). Nicotine content was next 
Table 2 Final ENDS attributes, levels and mean utilities, n=660
ENDS attributes Levels of ENDS attributes
Part-worth utilities,
mean (95% CI)
Harms of use Less harmful on my body as compared with tobacco cigarettes 88.96 (84.79 to 93.13)
Unknown harm on my body as compared with tobacco cigarettes −19.24 (−21.32 to 17.17)
Same amount of harm on my body as compared with tobacco cigarettes −22.45 (−24.90 to 19.99)
More harm on my body as compared with tobacco cigarettes −47.27 (−49.69 to 44.86)
General effects of use Helps me breathe easier and my clothes do not smell like tobacco 58.37 (55.07 to 61.68)
Helps me breathe easier but my clothes smell like tobacco −3.50 (−5.78 to 1.22)
Does not help me breathe easier but my clothes do not smell like 
tobacco
−12.35 (−14.78 to 9.93)
Does not help me breathe easier but still makes my clothes smell like 
tobacco
−42.52 (−45.15 to 39.89)
Tobacco cessation 7 of 10 people are able to quit tobacco cigarettes 41.92 (39.36 to 44.47)
5 of 10 people are able to quit tobacco cigarettes 19.98 (18.20 to 21.76)
2 of 10 people are able to quit tobacco cigarettes −12.79 (−14.84 to 10.73)
People are not able to quit smoking tobacco cigarettes −49.11 (−52.46 to 45.75)
Purchase price of 
product
$5 one-time purchase 52.41 (49.12 to 55.70)
$55 one-time purchase 12.40 (11.02 to 13.77)
$115 one-time purchase −26.04 (−27.92 to 24.17)
$175 one-time purchase −38.76 (−40.95 to 36.57)
Monthly cost of use $5 per month to use 47.50 (44.72 to 50.29)
$25 per month to use 16.68 (15.00 to 18.37)
$65 per month to use −22.16 (−23.91 to 20.42)
$100 per month to use −42.03 (−44.37 to 39.68)
Nicotine content* None (0 mg/mL) 10.89 (6.83 to 14.96)
Low (6 mg/mL) 18.29 (16.16 to 20.41)
Medium (12 mg/mL) 2.11 (−0.01 to 4.23)
High (24 mg/mL) −31.30 (−35.12 to 27.47)
Flavour availability Available in fruit, candy, coffee, wine and other flavours 15.88 (13.32 to 18.44)
Available in tobacco and menthol flavours 13.50 (11.94 to 15.05)
Available without any flavours −29.38 (-32.27 to 26.48)
Device design Very similar in size, weight, appearance, and feel to a tobacco cigarette 12.85 (11.16 to 14.54)
Somewhat similar in size, weight, appearance, and feel to a tobacco 
cigarette
14.47 (12.87 to 16.07)
Not similar at all in size, weight, appearance and feel to a tobacco 
cigarette
−27.32 (-29.98 to 24.66)
Modifiability Various parts can be modified 12.46 (10.68 to 14.23)
It cannot be modified −12.46 (-14.23 to 10.68)
*Nicotine levels corresponded to what the current literature designated as low, medium and high levels of nicotine.
ENDS, electronic nicotine delivery systems.
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most frequent (13%) and purchase price was third (12%). 
A goodness-of-fit χ2 test determined that the nine attri-
butes differed from expected and thus were not equally 
distributed among participants (p<0.001). Also, depen-
dent z-tests of the proportions of the second through 
ninth ranked attributes against harms of use found that 
all were significantly lower ranked and were less likely 
to be chosen as most important (range: ∆−83%–99%; 
p<0.001). Aside from nicotine content compared with harms 
of use, stepped tests of each attribute against its nearest 
found that only device design (p=0.005) and modifiability 
(p=0.020) were statistically significantly less important.
The nine attributes also statistically significantly 
differed from the expected distribution by the subgroups 
for age and gender (p<0.001). Pearson’s Χ2 tests of the 
relation between the age subgroups and most important 
attribute found that general effects was the most important 
attribute for younger adults as compared with other ages 
(p<0.001). Compared with younger and older adults, 
general effects was less likely to be the most important attri-
bute for middle-aged adults (p=0.029) and flavour avail-
ability was more likely to be most important (p=0.018). 
Compared with both younger and middle-aged adults, 
harms of use was more likely to be important (p=0.016) 
and flavour availability was less likely to be important 
(p=0.003). There were no statistically significant differ-
ences in the distribution of most important attributes by 
gender although harms of use (p=0.061) and cessation aid 
(p=0.075) approached significance.
DIsCussIOn
In our study of US adult ENDS consumers, we found that 
harms of use had the highest importance to consumers’ 
choice of an ENDS product. Other than cost (ie, purchase 
price and monthly cost), the attributes with the highest 
importance scores hinged on consumers’ perceptions of 
efficacy as a harm reduction strategy (harms of use), health 
benefit (general effects) and tobacco cessation (cessation 
aid), respectively. Consumers of different ages varied in 
importance they placed on different ENDS product char-
acteristics. As more evidence about these products’ ability 
to benefit or harm consumers is more fully understood, 
public health initiatives could target these perceptions. 
Variation by consumer group existed, which may allow for 
targeted interventions to reduce or enhance ENDS use in 
any given consumer group.
ENDS products are marketed as healthier than combus-
tible tobacco products,34 but the evidence regarding the 
impact of ENDS products on human health is slowly 
emerging. National Academies of Science, Engineering, 
and Medicine recently released a report on the public 
health consequences of ENDS products.35 While there is 
substantial evidence that, except for nicotine, exposure 
to potentially toxic substances from ENDS is significantly 
lower compared with combustible tobacco products, there 
is also substantial evidence that exposure to ENDS aero-
sols can induce lung dysfunction and oxidative stress in 
human tissue.36 The long-term effects on cardiovascular 
outcomes, cancer or other health conditions are unclear. 
Our work should add a sense of urgency to the push for 
ongoing research into the evidence for and against ENDS 
products as a harm reduction strategy. The idea that an 
Figure 2 Importance of ENDS characteristics, 
n=660. ENDS, electronic nicotine delivery systems.














Harms of use 326 (49%) 74 (44%) 114 (47%) 138 (55%)† 149 (46%) 177 (53%)
Nicotine content 85 (13%)* 26 (15%) 32 (13%) 27 (11%) 42 (13%) 43 (13%)
Purchase price of product 77 (12%) 14 (8%) 30 (12%) 33 (13%) 42 (13%) 35 (10%)
General effects of use 56 (9%) 26 (15%)† 13 (5%)† 17 (7%) 24 (7%) 32 (10%)
Tobacco cessation aid 45 (7%) 11 (6%) 16 (7%) 18 (7%) 28 (9%) 17 (5%)
Flavour availability 32 (5%) 10 (6%) 18 (7%)† 4 (2%)† 18 (5%) 14 (4%)
Monthly cost of use 27 (4%) 7 (4%) 11 (5%) 9 (4%) 17 (5%) 10 (3%)
Device design 10 (2%)* 1 (1%) 6 (2%) 3 (1%) 6 (2%) 4 (1%)
Modifiability 2 (0%)* 0 (0%) 2 (1%) 0 (0%) 0 (0%) 2 (1%)
* P<0.05 versus next higher ranked attribute for total sample.
†P<0.05 versus total sample for age groups.
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ENDS product was less harmful than tobacco cigarettes 
was extremely important to participants’ choice. The 
level that the product was ‘less harmful on my body as 
compared with tobacco cigarettes’ had the highest part-
worth utility of any attribute (88.96). Moreover, the level 
that the product ‘had the same amount of harm on my 
body as compared with tobacco cigarettes’ caused people 
to avoid choosing that product and had a negative utility 
(−22.45). Both the health effects and the use as a cessation 
aid had levels that are likely healthier and of more help 
in cessation than the evidence suggests. Yet in general, 
perceptions, including misperceptions, affect smokers’ 
behaviour.37 The look and feel of cigarette packaging 
appears to influence consumers’ use and may affect their 
perceptions’ of the healthiness and harm of the cigarettes 
within.38 A study of combustible tobacco labelling revealed 
that ‘additive-free’ or ‘natural’ labels on current cigarette 
brands were misperceived to be possibly less harmful than 
other brands of cigarettes and may reduce the efficacy 
of public health initiatives.39 Even efforts by the Federal 
Trade Commission to prohibit language that might create 
misperceptions of reduced harm in tobacco cigarettes has 
been unsuccessful.37 This (mis)perception of harm and 
health appears to strongly influence the choice of ENDS 
products. Further efforts, including those studying clear 
labelling and health warnings, are needed to explore how 
to align ENDS users’ perceptions of ENDS products with 
the evidence.
While harms of use had the highest importance score, 
the combined importance of purchase price and monthly cost 
was greater than harms of use, so the importance of finan-
cial burden on ENDS use should not be underestimated. 
If we combine the two cost-related attributes, purchase price 
and monthly cost, overall cost’s importance score would be 
24.1% as compared with 17.6% for health effects. A recent 
study of the cross-price elasticity of ENDS and tobacco 
cigarettes found that ENDS are partially substitutable 
for cigarettes.40 However, the availability of ENDS also 
reduced the number of individuals who reported they 
would quit smoking if cigarette costs increased by 20% 
(50.2% to 30.0%), revealing that ENDS may discourage 
smokers from quitting completely.41 Additionally, increase 
in the cost of ENDS products may shift consumers back 
towards combustible tobacco, though recent simulations 
found no relationship between cigarette prices and ENDS 
use.42 Taxation may reduce ENDS use but further work is 
needed to model the consequences of cost increase on 
ENDS use.
Potentially meaningful differences were found in the 
importance of ENDS product attributes and the most 
important attribute by different age groups. Younger 
and middle-aged adults found modifiability to be more 
important than older adults. While we did not see gender 
differences for attribute preferences, a Canadian DCE 
study of young women found that pack structure was the 
most important attribute driving ENDS use.14 The shape 
and structure of the device and packaging may be more 
important to a younger population. Younger adults were 
more likely to have general effects as their most important 
attribute while flavour availability was more likely to 
be most important to middle-aged adults and signifi-
cantly less likely to be most important to older adults. A 
systematic review of studies of consumers’ preference for 
flavour found it to be likely important to young people.7 
However, as with our own qualitative study, which was 
included in the review, many of the included studies did 
not have experimental designs.16 Interestingly, another 
Canadian DCE study of ENDS use found that younger 
smokers perceived cherry flavour as less harmful while 
older adults found tobacco flavour less harmful.15 While 
we found flavour availability was more important to 
middle-aged adults, we did not find older adults favoured 
tobacco flavour. However, both of these studies found 
that attributes related to the users’ health (harms of use in 
our case and health warnings in the Canadian study) were 
more important than flavour, and thus efforts to regulate 
flavours may not reduce ENDS use as much as other regu-
lations on other attributes, such as harms of use.
Our study has several important limitations. First, our 
study examines choice behaviour and not actual purchase 
behaviour. While we drew from a national online survey 
panel, our respondent population is limited to a conve-
nience sample. Additionally, best–worst scaling can be 
subject to attribute non-attendance where participants 
either fail to pay attention to an attribute or attributes, 
or attribute dominance where participants only pay atten-
tion to a single attribute. We found that only about 2% 
of participants did not attend to the majority of attri-
butes, though about 16% failed to attend to at least one 
attribute. No participant showed dominance behaviour. 
While there was some attribute non-attendance, best–
worst scaling inclines participants to make judgements 
about more attributes and does not invite as much 
attribute non-attendance or dominance as can be seen 
in other standard DCEs. However, it seems more likely 
that socially desirable responses could bias respondents’ 
choices within best–worst scaling than other DCEs.24 
Lastly, while we did extensive pretesting, it is possible that 
different participants interpreted different attributes and 
levels differently. For example, it is possible that partici-
pants viewed the monthly cost of use in relation to their 
own use and thus the responses to monthly cost may need 
to be viewed with caution.
COnClusIOn
A variety of ENDS product attributes are important to 
consumers. Harms of use had the highest importance 
to consumers’ choice of an ENDS product. Other than 
cost, the attributes with the highest importance scores 
hinged on consumers’ perceptions of efficacy as a harm 
reduction strategy (harms of use), general benefit (general 
effects) and tobacco cessation (cessation aid), respectively. 
Consumers differed by age group in some of the more 
important attributes. Though the overall importance of 
ENDS product attributes was similar, efforts to increase 
8 Kistler CE, et al. BMJ Open 2019;9:e027247. doi:10.1136/bmjopen-2018-027247
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or decrease ENDS use could be tailored to these group 
differences.
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